CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 12, 2019--
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome
therapeutics platform company developing a novel class of biological
drugs that are designed to treat disease by restoring the function of a
dysbiotic microbiome, today announced that it is commencing an
underwritten registered public offering of $60.0 million of shares of
its common stock. As part of this offering, Seres intends to grant the
underwriters a 30-day option to purchase up to an additional $9.0
million of shares of its common stock. All of the shares in the proposed
offering are to be sold by Seres.
Goldman Sachs & Co. LLC and Cowen and Company, LLC are acting as joint
book-running managers for the offering. The offering is subject to
market and other conditions, and there can be no assurance as to whether
or when the offering may be completed, or as to the actual size or terms
of the offering.
The common stock described are being offered by Seres pursuant to a
shelf registration statement on Form S-3 (No. 333-216735), including a
prospectus, which was declared effective by the Securities and Exchange
Commission (“SEC”) on March 24, 2017. A preliminary prospectus
supplement to the prospectus describing the terms of the offering was
filed with the SEC on June 5, 2019, and a final prospectus supplement
will be filed with the SEC. The offering will be made only by means of a
written prospectus and prospectus supplement that form a part of the
effective registration statement. Copies of the preliminary prospectus
supplement and accompanying prospectus relating to the offering may be
obtained, when available, by contacting: Goldman Sachs & Co. LLC by mail
at Prospectus Department, 200 West Street, New York, New York 10282,
Attention: Prospectus Department, by telephone at (866) 471-2526, by fax
at (212) 902-9316, or by email at firstname.lastname@example.org
or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by
telephone at (631) 592-5973.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or jurisdiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005892/en/
Source: Seres Therapeutics, Inc.
Carlo Tanzi, Ph.D., Seres Therapeutics, 617-203-3467
President, Investor Relations and Corporate Communications